Fate Therapeutics announces pricing of $100M underwritten offering and concurrent private placement

seekingalpha03-19

Fate Therapeutics (NASDAQ:FATE) on Tuesday announced the pricing of an underwritten offering of 14,545,454 shares of its common stock at an offering price of $5.50 per share. The offering includes ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2420217782?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-03-19 20:56","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"2420217782","market":"fut","top_or_hot":-1,"title":"Fate Therapeutics announces pricing of $100M underwritten offering and concurrent private placement","media":"seekingalpha","content":"<div>\n<p>Fate Therapeutics (NASDAQ:FATE) on Tuesday announced the pricing of an underwritten offering of 14,545,454 shares of its common stock at an offering price of $5.50 per share. The offering includes ...</p>\n\n<a href=\"https://seekingalpha.com/news/4081017-fate-therapeutics-announces-pricing-of-100m-underwritten-offering-and-concurrent-private-placement\">Source Link</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Fate Therapeutics announces pricing of $100M underwritten offering and concurrent private placement</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFate Therapeutics announces pricing of $100M underwritten offering and concurrent private placement\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-03-19 20:56 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/4081017-fate-therapeutics-announces-pricing-of-100m-underwritten-offering-and-concurrent-private-placement><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Fate Therapeutics (NASDAQ:FATE) on Tuesday announced the pricing of an underwritten offering of 14,545,454 shares of its common stock at an offering price of $5.50 per share. The offering includes ...</p>\n\n<a href=\"https://seekingalpha.com/news/4081017-fate-therapeutics-announces-pricing-of-100m-underwritten-offering-and-concurrent-private-placement\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"FATE","symbol_name":"Fate Therapeutics Inc","start_time":0,"source_url":"https://seekingalpha.com/news/4081017-fate-therapeutics-announces-pricing-of-100m-underwritten-offering-and-concurrent-private-placement","article_id":"2420217782","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2420217782","pubTimestamp":1710853018,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"Fate Therapeutics  on Tuesday announced the pricing of an underwritten offering of 14,545,454 shares of its common stock at an offering price of $5.50 per share. The offering includes participation from new and existing institutional investors, including Adage Capital Partners, Boxer Capital among others.  In addition, the company announced the pricing of a concurrent private placement of pre-funded warrants to purchase 3,636,364 shares of its common stock at a purchase price of $5.499 per pre-funded warrant. The gross proceeds from the underwritten offering and private placement are expected to be about $100 million. All of the shares and pre-funded warrants are to be sold by the company. The financing is expected to close on or about March 21. FATE -0.56% premarket to $7.0. Source: Press Release    More on Fate Therapeutics  Fate Therapeutics Update: A Rally Based On Little Increases Near-Term Risks Seeking Alpha’s Quant Rating on Fate Therapeutics Historical earnings data for Fate T","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"FATE":"Fate Therapeutics Inc","BK4139":"生物科技"},"translate_title":"Fate Therapeutics宣布1亿美元承销发行和同时私募的定价","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"FATE":1},"content_text":"Fate Therapeutics (NASDAQ:FATE) on Tuesday announced the pricing of an underwritten offering of 14,545,454 shares of its common stock at an offering price of $5.50 per share. The offering includes participation from new and existing institutional investors, including Adage Capital Partners, Boxer Capital among others.  In addition, the company announced the pricing of a concurrent private placement of pre-funded warrants to purchase 3,636,364 shares of its common stock at a purchase price of $5.499 per pre-funded warrant. The gross proceeds from the underwritten offering and private placement are expected to be about $100 million. All of the shares and pre-funded warrants are to be sold by the company. The financing is expected to close on or about March 21. FATE -0.56% premarket to $7.0. Source: Press Release    More on Fate Therapeutics  Fate Therapeutics Update: A Rally Based On Little Increases Near-Term Risks Seeking Alpha’s Quant Rating on Fate Therapeutics Historical earnings data for Fate Therapeutics Financial information for Fate Therapeutics","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2420217782"}